Do this Before Elon’s Reveal on January 22nd

Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.

Daniel R. Passeri net worth and biography

Daniel Passeri Biography and Net Worth

CEO of Cue Biopharma

Dan Passeri is a seasoned biotechnology executive with over 20 years of experience managing drug discovery and development programs as well as business development activities on behalf of publicly traded companies, with deep experience in both oncology and strategic partnership generation. Prior to joining Cue Biopharma, Mr. Passeri served as President and Chief Executive Officer as well as Vice Chairman of the Board of Curis, Inc. Prior to joining Curis, he was employed by GeneLogic Inc., most recently as Senior Vice President, Corporate Development and Strategic Planning. Prior to his work at GeneLogic, Mr. Passeri served as Director of Technology Management at Boehringer Mannheim. Mr. Passeri received a J.D. from the National Law Center at George Washington University, an M.Sc. in Biotechnology from the Imperial College of Science, Technology and Medicine at the University of London and a B.S. in Biology from Northeastern University.

What is Daniel R. Passeri's net worth?: The estimated net worth of Daniel R. Passeri is at least $176,098.46 as of December 16th, 2024. Mr. Passeri owns 164,578 shares of Cue Biopharma stock worth more than $176,098 as of December 18th. This net worth approximation does not reflect any other investments that Mr. Passeri may own. Additionally, Mr. Passeri receives a salary of $607,980.00 as CEO at Cue Biopharma. Learn More about Daniel R. Passeri's net worth.
How old is Daniel R. Passeri?: Mr. Passeri is currently 63 years old. There are 5 older executives and no younger executives at Cue Biopharma. Learn More on Daniel R. Passeri's age.
What is Daniel R. Passeri's salary?: As the CEO of Cue Biopharma, Inc., Mr. Passeri earns $607,980.00 per year. Learn More on Daniel R. Passeri's salary.
How do I contact Daniel R. Passeri?: The corporate mailing address for Mr. Passeri and other Cue Biopharma executives is 21 ERIE STREET, CAMBRIDGE MA, 02139. Cue Biopharma can also be reached via phone at (617) 949-2680 and via email at [email protected]. Learn More on Daniel R. Passeri's contact information.
Has Daniel R. Passeri been buying or selling shares of Cue Biopharma?: Over the course of the past ninety days, Daniel R. Passeri has bought $30,900.00 in Cue Biopharma stock. Most recently, on Monday, December 16th, Daniel R. Passeri bought 30,000 shares of Cue Biopharma stock. The stock was acquired at an average cost of $1.03 per share, with a total value of $30,900.00. Following the completion of the transaction, the chief executive officer now directly owns 164,578 shares of the company's stock, valued at $169,515.34. Learn More on Daniel R. Passeri's trading history.
Who are Cue Biopharma's active insiders?: Cue Biopharma's insider roster includes Kerri-Ann Millar (CFO), Daniel Passeri (CEO), Kenneth Pienta (Insider), and Anish Suri (Insider). Learn More on Cue Biopharma's active insiders.
Are insiders buying or selling shares of Cue Biopharma?: In the last year, Cue Biopharma insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $30,900.00. The most recent insider tranaction occured on December, 16th when CEO Daniel R Passeri bought 30,000 shares worth more than $30,900.00. Insiders at Cue Biopharma own 12.3% of the company. Learn More about insider trades at Cue Biopharma.
Information on this page was last updated on 12/16/2024.

Daniel R. Passeri Insider Trading History at Cue Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2024	Buy	30,000	$1.03	$30,900.00	164,578
8/14/2023	Buy	3,000	$2.86	$8,580.00	134,578
9/24/2021	Buy	3,400	$14.72	$50,048.00
6/21/2019	Buy	1,377	$7.26	$9,997.02
6/6/2019	Buy	3,000	$6.90	$20,700.00
8/16/2018	Buy	6,000	$8.09	$48,540.00
6/29/2018	Buy	1,600	$11.97	$19,152.00

Daniel R. Passeri Buying and Selling Activity at Cue Biopharma

Cue Biopharma Company Overview

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.07

$1.01

$1.22

50 Day Range

MA: $1.32

$0.94

$1.87

2 Week Range

Now: $1.07

$0.45

$3.20

Volume

451,012 shs

Average Volume

453,450 shs

Market Capitalization

$67.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Do this Before Elon’s Reveal on January 22nd

From Brownstone Research | Ad

I urge you to watch this video now.

Daniel Passeri Biography and Net Worth

What is Daniel R. Passeri's net worth?

How old is Daniel R. Passeri?

What is Daniel R. Passeri's salary?

How do I contact Daniel R. Passeri?

Has Daniel R. Passeri been buying or selling shares of Cue Biopharma?

Who are Cue Biopharma's active insiders?

Are insiders buying or selling shares of Cue Biopharma?